Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associated steatohepatitis (MASH).

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the results of a mid-stage trial are ...

When it comes to achieving that perfect mash though, people rely on loads of different methods – each household has their own way of doing it. I’ve delved so heavily into potato recipes over the last ...

Metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), is a more severe form of fatty liver disease that causes inflammation and damage. MASH ...